Breaking World Pharma News

Edible 'security tag' to protect drugs from counterfeit

Manufacturing prescription drugs with distinct markings, colors, shapes or packaging isn't enough to protect them from counterfeiting, U.S. Drug Enforcement Administration reports have shown. Purdue University researchers are aiming to stump counterfeiters with an edible "security tag" embedded into medicine.

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab.

Women's blood vessels age faster than men's

New research from the Smidt Heart Institute at Cedars-Sinai showed for the first time that women's blood vessels - including both large and small arteries - age at a faster rate than men's. The findings, published Wednesday in the journal JAMA Cardiology, could help to explain why women tend to develop different types of cardiovascular disease and with different timing than men.

Roche and Illumina partner to broaden patient access to genomic testing

Roche (SIX: RO, ROG; OTCQX: RHHBY) has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. As the understanding of the genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.

Exosomes promote remarkable recovery in stroke

It's been almost a quarter century since the first drug was approved for stroke. But what's even more striking is that only a single drug remains approved today. In a publication appearing this month in the journal Translational Stroke Research, animal scientists, funded by the National Institutes of Health, present

Amgen announces global diagnostic collaborations

Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510.

Vitamin B6, leukemia's deadly addiction

Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division.

Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim's leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company's extensive range of therapeutic antibodies targeting this pathway.

Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone

The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The bush also provides the chemical bouvardin, which the lab of University of Colorado Cancer Center and CU Boulder researcher, Tin Tin Su, PhD, and others have shown to slow a cancer's ability to make proteins that tell cancer cells to grow and spread.

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors

The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract,

WORLDPHARMANEWS

Breaking World Pharma News

Edible 'security tag' to protect drugs from counterfeit

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer

Women's blood vessels age faster than men's

Roche and Illumina partner to broaden patient access to genomic testing

Exosomes promote remarkable recovery in stroke

Amgen announces global diagnostic collaborations

Vitamin B6, leukemia's deadly addiction

Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases

Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs